Conditions: Diabetes Diabetes Mellitus, Type 2
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 415
Healthy volunteers: no

Brief summary:
This trial was conducted in Europe,Asia and Africa. Study participants were randomised evenly to treatment with semaglutide (0.1 mg QW - 1.6 mg QW, 6 treatment arms, placebo or liraglutide (1.2 mg QD, or 1.8 mg QD).Treatment allocation to semaglutide or placebo was double-blind, whereas liraglutide treatment was administered open-label.Primary efficacy parameter was HbA1c and the treatment duration was 12 weeks.

Detailed description:

Arms:
arm 1: None arm 2: None arm 3: None arm 4: None arm 5: None arm 6: None arm 7: None arm 8: None arm 9: None arm 10: None arm 11: None arm 12: None arm 13: None arm 14: None

Interventions: intervention 1: semaglutide intervention 2: semaglutide intervention 3: semaglutide intervention 4: semaglutide intervention 5: semaglutide intervention 6: semaglutide intervention 7: placebo intervention 8: placebo intervention 9: placebo intervention 10: placebo intervention 11: placebo intervention 12: liraglutide intervention 13: liraglutide
Intervention descriptions: intervention 1: 0.1 mg, once weekly, s.c. injection intervention 2: 0.2 mg, once weekly, s.c. injection intervention 3: 0.4 mg, once weekly, s.c. injection intervention 4: 0.8 mg, once weekly, s.c. injection intervention 5: 0.8 mg with titration, once weekly, s.c. injection intervention 6: 1.6 mg with titration, once weekly, s.c. injection intervention 7: 0.1 mg, once weekly, s.c. injection intervention 8: 0.2 mg, once weekly, s.c. injection intervention 9: 0.4 mg, once weekly, s.c. injection intervention 10: 0.8 mg with titration, once weekly, s.c. injection intervention 11: 1.6 mg, once weekly, s.c. injection intervention 12: 1.2 mg with titration, once daily, s.c. injection intervention 13: 1.8 mg with titration, once daily, s.c. injection

Protocol document: